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ABSTRACT
Background: The number of APOE-ε4 alleles is a major nonmod-
ifiable risk factor for sporadic Alzheimer disease (AD). There is
increasing evidence on the benefits of dietary DHA (22:6n–3) before
the onset of AD symptoms, particularly in APOE-ε4 carriers. Brain
alterations in the preclinical stage can be detected by structural MRI.
Objectives: We aimed, in middle-aged cognitively unimpaired
individuals at increased risk of AD, to cross-sectionally investigate
whether dietary DHA intake relates to cognitive performance and to
MRI-based markers of cerebral small vessel disease and AD-related
neurodegeneration, exploring the effect modification by APOE-ε4
status.
Methods: In 340 participants of the ALFA (ALzheimer and FAm-
ilies) study, which is enriched for APOE-ε4 carriership (n = 122,
noncarriers; n = 157, 1 allele; n = 61, 2 alleles), we assessed
self-reported DHA intake through an FFQ. We measured cognitive
performance by administering episodic memory and executive
function tests. We performed high-resolution structural MRI to
assess cerebral small vessel disease [white matter hyperintensities
(WMHs) and cerebral microbleeds (CMBs)] and AD-related brain
atrophy (cortical thickness in an AD signature). We constructed
regression models adjusted for potential confounders, exploring the
interaction DHA × APOE-ε4.
Results: We observed no significant associations between DHA
and cognitive performance or WMH burden. We observed a
nonsignificant inverse association between DHA and prevalence
of lobar CMBs (OR: 0.446; 95% CI: 0.195, 1.018; P = 0.055).
DHA was found to be significantly related to greater cortical
thickness in the AD signature in homozygotes but not in nonho-
mozygotes (P-interaction = 0.045). The association strengthened
when analyzing homozygotes and nonhomozygotes matched for risk
factors.
Conclusions: In cognitively unimpaired APOE-ε4 homozygotes,
dietary DHA intake related to structural patterns that may result in
greater resilience to AD pathology. This is consistent with the current
hypothesis that those subjects at highest risk would obtain the largest
benefits from DHA supplementation in the preclinical stage. This
trial was registered at clinicaltrials.gov as NCT01835717. Am J
Clin Nutr 2021;113:1627–1635.
Keywords: omega-3 fatty acids, cognition, markers, white matter
hyperintensities, cerebral small vessel disease, brain atrophy
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Introduction
Alzheimer disease (AD) imposes a huge socioeconomic
burden. Given that at the moment there are no approved disease-
modifying drugs for AD, preventive strategies are of paramount
importance (1). There is a large body of observational evidence
on the cognitive benefits of regular consumption of fatty fish
(2), which is the main dietary source of DHA (22:6n–3). This
fatty acid is critical for brain function and ameliorates AD
features (3). Whether dietary intake of DHA relates to cognitive
decline and AD is still under debate. A 2015 meta-analysis of
21 epidemiologic studies reported a significantly reduced risk of
AD for DHA intake (4). However, randomized controlled trials on
DHA supplementation and cognition have yielded mixed results
(5). A plausible reason to explain part of this controversy is
the influence of the genetic background, in particular the APOE
genotype (2, 5, 6), which is the strongest genetic risk factor
for sporadic AD (7). In this regard, cognitive benefits of DHA
supplementation have been reported in cognitively unimpaired
APOE-ε4 carriers, but not in those with AD symptomatology
(5, 6). This emphasizes the need for interventions in this
population segment before clinical symptoms appear (the so-
called preclinical stage).
ApoE has a critical role in lipid transport. APOE-ε4 carriers
present a specific isoform of apoE (apoE-ε4) that is less efficient
in this function and, in addition, contributes to AD pathogenesis
by affecting multiple other pathways, including cerebrovascular
derangements and faster brain accumulation of amyloid-β, a
pathological hallmark of AD (8). Given that apoe-ε4 operates
from the earliest stages of life, it has been suggested that
apoE-ε4-related cumulative changes could be observed by MRI
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in the brains of APOE-ε4 carriers long before the onset of
cognitive decline. On one hand, APOE-ε4 carriers, in particular
APOE-ε4 homozygotes, have an increased burden of MRI
markers of cerebral small vessel disease, including white matter
hyperintensities (WMHs) (9) and cerebral microbleeds (CMBs)
(10), which may confer an increased risk of stroke and AD (11).
On the other hand, most studies have reported accelerated atrophy
in AD-sensitive regions, related to APOE-ε4 carriership (12).
Given the increasing evidence of APOE-ε4 load as a
factor in brain vulnerability in the preclinical stage of AD,
we hypothesized that in middle-aged cognitively unimpaired
individuals, APOE-ε4 status would modulate the associations
of dietary DHA with cognitive performance (direct association)
and with MRI-assessed structural brain alterations (inverse
association). To ascertain this, we assessed self-reported dietary
intake of DHA and searched for associations with performance
in neuropsychological testing (episodic memory and executive
function), MRI markers of cerebral small vessel disease (WMHs
and CMBs), and early AD-related neurodegeneration (cortical
thickness in AD-vulnerable regions) in a population enriched
with APOE-ε4 carriership (n = 122, noncarriers; n = 157,
1 allele; n = 61, 2 alleles).
Methods
Participants
We conducted this cross-sectional study (NCT01835717) in
participants from the ALFA (ALzheimer and FAmilies) study,
which is being carried out at the Barcelonaβeta Brain Research
Center (BBRC). The protocol of the ALFA study was approved
by the Independent Ethics Committee of the “Parc de Salut
Mar” (Barcelona, Spain). Detailed information on the study can
be found elsewhere (13). In brief, the ALFA parent cohort is
comprised of 2743 cognitively unimpaired middle-aged subjects
(45–75 y), many of them kindred of AD patients (47.4% of the
participants had ≥1 parent diagnosed with AD before the age of
75 y). To ensure unimpaired cognitive status, an initial evaluation
of the participants’ neuropsychological status was performed
via 4 screening tests. We excluded participants with a Mini-
Mental State Examination score < 26, or a Memory Impairment
Screen score < 6, or a score on the Time-Orientation subtest
of the Barcelona Test II <68, or a Semantic fluency (animals)
score < 12. An additional exclusion criterion was a score > 0
on the Clinical Dementia Rating scale, which is derived from a
standard clinical impression interview performed with both the
participant and a reliable informant to assess cognitive status.
At baseline, ALFA participants also provided sociodemographic,
anthropometric, clinical, and lifestyle data, along with a blood
sample for further genetic analysis, including APOE genotyping.
We selected a subgroup of 608 ALFA participants without MRI
contraindications, preferentially including APOE-ε4 and APOE-
ε2 carriers, to participate in the neuroimaging study, which was
also approved by the Ethics Committee of the “Parc de Salut
Mar” (Barcelona, Spain). From the 608 participants invited to
participate in this study, 595 agreed to undergo MRI and 575
provided valid MRI scans. Because of the protective effects on
AD risk of the ε2/ε3 and in particular the ε2/ε2 genotype (14),
for this substudy we excluded participants with these genotypes
(n = 119, 7 of which were ε2/ε2). All participants accepted the
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Sociodemographic, clinical, and lifestyle data
Data were registered either during the clinical interview or
through online self-administered questionnaires. All participants
were asked about their family and personal medical history,
and medication use was recorded. Participants were considered
“hypertensive” if ≥1 of the following conditions was met:
1) self-reported diagnosis; 2) current use of antihypertensive
medication; 3) measured systolic blood pressure > 140 mm
Hg. “Hypercholesterolemia” was categorized as present if
self-reported or if subjects were using cholesterol-lowering
medications. Family history of AD was recorded as previously
reported (13). In brief, family history was divided into 4 possible
groups: “no AD family history,” “maternal,” “paternal,” and
“both parents.” This classification was only considered positive if
the relative was younger than 75 y at the time of onset of cognitive
symptoms. Height, weight, and blood pressure were measured by
standard methods.
Participants were asked to provide dietary data by completing
a web-based self-administered FFQ. This validated questionnaire
has a closed list of 166 items representing typical foods in
northeastern Spain (15), including 16 items related to fish and
seafood: lean fish; salmon; trout; uncanned sardine; uncanned
tuna; mackerel; uncanned bivalves; shrimp, prawn, and crayfish;
octopus, baby squid, and squid; tuna canned in oil; tuna canned in
brine; sardines canned in oil; sardines canned in brine; anchovy
fillets canned in oil; canned clams; and canned cockles. For
each food item, participants were asked to indicate their usual
consumption from 9 frequency categories, ranging from never or
less than once per month to ≥6 times/d. The questionnaire also
contained an open section to admit additions to the food list for
foods, beverages, and nutritional supplements not included in the
closed list of food items. Intakes were converted to mean grams
per day using standard reference portion sizes, defined by natural
(e.g., 1 orange, 1 slice of bread) or household units (e.g., 1 spoon,
1 cup, 1 glass). We computed intakes of energy and fatty acids
including DHA using Spanish food composition tables and the
Medisystem 2000 software (Conaycite).
Cognitive testing
During neuropsychological evaluation, participants were ad-
ministered a cognitive test battery. This battery assessed episodic
verbal memory by means of the Memory Binding Test (MBT)
(16, 17), as well as executive and reasoning functions using
the Wechsler Adult Intelligence Scale (WAIS)-IV including psy-
chomotor speed, visual processing, executive function, and non-
verbal and verbal reasoning (Coding, Visual Puzzles, Digit Span,
Matrix Reasoning, and Similarities) (18). We computed 2 cogni-
tive composites to assess global episodic memory and executive
function by creating z scores for the cognitive measures from
the MBT and from the WAIS-IV subtests, respectively. These
global measures were calculated by averaging normalized age-
and education-regressed scores of all subtests in each domain. As
with the individual cognitive tests, higher scores in the different
composites represent better cognitive performance, whereas
lower scores correspond to worse cognitive performance.
MRI acquisition and processing
MRI scans were acquired on a 3.0-T scanner (GE Discovery
MR750 W 3T) using a protocol that included 1 T1-weighted
sequence and 3 T2-weighted sequences [fluid-attenuated in-
version recovery (FLAIR), fast spin echo (FSE), and gradient
echo (GRE)]. The T1-weighted sequence had an isotropic voxel
size of 1 mm3 with a matrix size of 256 × 256 × 160,
repetition time (TR) = 8.3 ms, echo time (TE) = 3.7 ms,
inversion time (TI) = 450 ms, flip angle = 8◦. T2 and T2∗-
weighted sequences, with a voxel size of 1 × 1 × 3 mm,
were as follows: FLAIR: TR/TE/TI = 11,000/90/2600 ms, flip
angle = 160◦; FSE: TR/TE = 5000/85 ms, flip angle = 110◦;
and GRE: TR/TE = 1300/23 ms, flip angle = 15◦. A trained
neuroradiologist visually assessed all scans for quality and
incidental findings (19).
FLAIR images were assessed for WMHs of presumably
vascular origin and automatically segmented using a Bayesian
algorithm, as detailed in Sudre et al. (20). Details of the imaging
processing can be found in Salvadó et al. (21). Subcortical
volumes, cortical thickness, and surface area measures were
estimated from 3D T1 MRI using Freesurfer version 5.3.0 (ht
tps://surfer.nmr.mgh.harvard.edu) as previously described (22).
All segmentations were visually inspected. We computed the
AD-signature meta-region of interest consisting of the surface-
area weighted average mean cortical thickness in the entorhinal,
inferior temporal, middle temporal, and fusiform regions, as
described in Jack et al. (23).
CMBs were defined as foci of hypointensity < 10 mm in di-
ameter on the T2∗ GRE images. The visual assessment of CMBs
was performed by consensus of 2 experienced raters blinded to all
clinical data and APOE genotype according to the Brain Observer
Microbleeds Scale (BOMBS) Criteria (24). Briefly, the BOMBS
Criteria are a classification system devised to improve levels
of interrater agreement about the presence, number, size, and
location of CMBs including 7 anatomical locations, including
cortex/gray-white matter junction, subcortical white matter, basal
ganglia, internal and external capsule, thalamus, brainstem, and
cerebellum. Cortex/gray-white matter junction and subcortical
white matter were considered “lobar” locations, whereas basal
ganglia, internal and external capsule, thalamus, and cerebellum
were considered “deep” locations. The localization of CMBs was
marked using ITK-snap (www.itksnap.org) (25).
Statistical analyses
The lack of available literature on the effect of APOE-ε4 geno-
type on self-reported DHA intake and cognition/neuroimaging
in cognitively unimpaired participants (5), coupled with the
fact that this study was initially conceived as an exploratory
substudy to be conducted in ALFA participants with available
data, precluded us from running an a priori power calculation for
this substudy (26). However, we conducted sensitivity analyses
by using free G-Power 3.1.9.4 software (http://www.gpower.hhu
.de) (27) (Supplemental File 1).
We expressed categorical variables as frequencies and per-
centages, whereas quantitative variables following a normal
distribution were expressed as mean (95% CI). The normal distri-
bution of continuous variables was assessed by the Kolmogorov–
Smirnov test. Skewed variables, which are reported as medi-
ans and IQRs, were rank-transformed for further parametric
analyses.
We assessed differences between participants included in the
analyses and the whole ALFA population by 1-factor ANOVA,
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We next constructed regression models to search for associa-
tions between self-reported DHA intake (predictor) and episodic
memory and executive function composite scores, WMH burden,
prevalence of CMBs, and cortical thickness in the AD signature
(outcomes). We did not consider the presence of CMBs in deep
brain and lacunar infarcts as outcomes owing to the low number
of cases in our population study (n = 14 and n = 12, respectively).
For each outcome, we tested the distinct models of APOE-
ε4 penetrance, namely the dominant, recessive, and additive
effects, as proposed for the analysis of quantitative trait loci (28).
Briefly, an additive model predicts an incremental response of the
quantitative trait according to the allelic load, whereas a dominant
model predicts a common response to 1 copy or 2 copies of the
risk allele (i.e., ε4-carriers compared with noncarriers). Finally, a
recessive model predicts a common response to 0 copies or 1 copy
of the risk allele (i.e., noncarriers and ε4-heterozygotes compared
with ε4-homozygotes).
We first searched for associations between DHA and episodic
memory and executive function composites using linear re-
gression models, adjusting for gender and total energy intake.
Given the documented brain benefits of dietary α-linolenic acid
(ALA; 18:3n–3) (the vegetable n–3) (29), we also included self-
reported dietary intake of ALA as a confounder. Second, we
explored the association between DHA and WMH burden by
linear regression models, adjusting for total intracranial volume,
gender, age, BMI, hypertension, hypercholesterolemia, total
energy intake, and ALA. Third, we evaluated the associations
between DHA and the presence of CMBs (in any brain area,
and in lobar regions). To this end, we constructed logistic
regression models, adjusting for the variables included in the
WMH models, except for total intracranial volume. Fourth, we
explored the association between DHA and cortical thickness
in the AD signature by constructing identical models to those
designed for WMHs, but excluding total intracranial volume
as a covariate. For each outcome, we further constructed an
additional model to assess the interaction DHA × APOE-
ε4. In the event of a statistically significant DHA × APOE-
ε4 interaction, we stratified the sample by APOE-ε4 status
to further search for group-specific associations. To reduce
the residual confounding, we further performed a propensity
score analysis using a 1:1 matching for selected adjusting
covariates, including gender, age (within 2.5 y), BMI (nor-
moweight/overweight/obese), and, when possible, hypertension
(yes/no) and hypercholesterolemia (yes/no). We then determined
the Pearson correlation coefficients between DHA and standard-
ized residuals outputted from general linear models including the
covariates.
For all regression analyses, standard diagnostic checks on the
residuals from the fitted models showed no evidence of any
failure of the assumptions of normality and homogeneity of the
residual variance.
Statistical significance was set at the P < 0.05 level in all cases.
Analyses were performed using SPSS software, release 20.0
(IBM Corp.). Figures were built using R software (R Foundation
for Statistical Computing; http://www.r-project.org/).
Results
Of 456 participants that were not APOE-ε2/ε2 or APOE-
ε2/ε3 with MRI scans, 12 were removed from the study
owing to the presence of incidental findings, motion artifacts,
or segmentation problems. After further excluding participants
with incomplete dietary data (n = 64) and those who reported
total energy intake outside predefined limits [>4000 or <800
kcal/d in men and >3500 or <500 kcal/d in women (30),
n = 40], 340 participants remained in the present analyses. None
of the participants reported consumption of fish oil or foods
supplemented with DHA. Supplemental Figure 1 depicts the
flowchart of participants throughout the study. Compared with
the whole cohort, participants included in the analyses more
often had a prior history of hypercholesterolemia and prevalence
of APOE-ε4 carriership (P < 0.001, both). Table 1 shows the
characteristics of the study’s population by number of APOE-ε4
alleles. Supplemental Table 1 displays information regarding
the 40 participants excluded for reporting total energy intake
outside the predefined limits.
Results of the association between self-reported dietary DHA
intake and cognitive performance are presented in Table 2
(episodic memory) and Table 3 (executive function). We did
not find statistically significant associations between DHA intake
and episodic memory or executive function. Table 4 displays
multivariate associations for WMH burden. As observed, no
statistically significant associations were observed for DHA
or the interaction DHA × APOE-ε4 in any model. Table 5
presents multiple logistic regression models for the presence
of CMBs. DHA showed a trend toward a lower prevalence
of lobar CMBs (P ≤ 0.055, whichever was the model). The
interaction DHA × APOE-ε4 was found to be statistically
nonsignificant in any model. We next searched for associations
between dietary DHA and cortical thickness in the AD signature
(Table 6). No statistically significant associations were observed
for DHA. However, the interaction DHA × APOE-ε4 in
the recessive model (P = 0.045) prompted us to search for
associations after separating by APOE-ε4 homozygosis. With
this approach, we observed a statistically significant direct
association between DHA and cortical thickness in the AD
signature in APOE-ε4 homozygotes but not in nonhomozygotes
(Supplemental Table 2). To reduce the residual confounding,
we next performed a propensity score analysis by matching
each homozygote to a nonhomozygote of the cohort. Given
that 2 homozygotes could not be matched because of BMI
extreme values, 59 pairs (n = 118) were considered for this
subanalysis. Supplemental Table 3 details the characteristics
of the 2 groups. No between-group significant differences were
observed concerning the variables used for matching, predictor,
or outcome of interest. With this approach, the strength of
the DHA × APOE-ε4 interaction increased (Supplemental
Table 4). Like the model including the total population, a
statistically significant direct association between DHA and
cortical thickness in the AD signature was observed in APOE-
ε4 homozygotes but not in matched nonhomozygotes (Figure 1,
Supplemental Table 5).
Finally, sensitivity results including the 40 participants ex-
cluded for reporting total energy intake outside the predefined
limits can be found in Supplemental Tables 6 (episodic memory
composite scores), 7 (executive function composite scores), 8
(WMH burden), 9 (CMBs), and 10 (cortical thickness in the
AD signature). For the latter, the statistical significance for the
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TABLE 1 Demographic, clinical, genetic, lifestyle, and neuroimaging data of the study population by number of APOE-ε4
alleles1
APOE-ε4 alleles, n
Variable None (n = 122) One2 (n = 157) Two (n = 61)
Women 80 (65.6) 81 (51.6) 40 (65.6)
Age, y 58.7 (57.2, 60.2) 58.0 (56.8, 59.1) 54.2 (52.6, 55.8)
Parental history of AD before 75 y
No AD family history 57 (46.7) 69 (43.9) 26 (42.6)
Paternal 17 (13.9) 30 (19.1) 8 (13.1)
Maternal 48 (39.3) 52 (33.1) 21 (34.4)
Both parents 0 (0.0) 6 (3.8) 6 (9.8)
Hypertension 32 (26.2) 32 (20.4) 12 (19.7)
Hypercholesterolemia 47 (38.5) 56 (35.7) 24 (39.3)
Years of education 13.5 (12.9, 14.2) 14.0 (13.4, 14.5) 13.5 (12.6, 14.4)
Smoking
Never smoker 17 (13.9) 28 (17.8) 5 (8.3)
Current smoker 31 (25.4) 34 (21.7) 19 (31.7)
Former smoker 74 (60.7) 95 (60.5) 36 (60.0)
Weight, kg 73.1 (70.8, 75.5) 74.7 (72.4, 77.0) 72.9 (69.3, 76.4)
BMI, kg/m2 26.7 (26.0, 27.3) 26.8 (26.1, 27.4) 27.0 (25.9, 28.1)
Dietary data
Energy, kcal/d 2467 (2369, 2565) 2430 (2332, 2527) 2353 (2217, 2489)
Seafood, g/d 107 (97, 117) 106 (94, 119) 114 (93, 134)
Fatty fish, g/d 60 (53, 67) 55 (50, 60) 60 (46, 74)
DHA, g/d 0.82 (0.74, 0.90) 0.76 (0.70, 0.82) 0.77 (0.66, 0.88)
ALA, g/d 1.06 (1.01, 1.12) 1.04 (0.98, 1.09) 1.06 (0.98, 1.14)
Neuroimaging data
WMH burden, cm3 2.19 [1.99–3.98] 2.02 [0.99–3.69] 1.91 [1.11–4.37]
Prevalence of microbleeds, any brain area 21 (17.2) 29 (18.7) 12 (19.7)
Prevalence of microbleeds, lobar brain 19 (15.6) 22 (14.2) 9 (14.8)
Prevalence of microbleeds, deep brain 3 (2.5) 7 (4.5) 4 (6.6)
Lacunar infarcts 5 (4.1) 7 (4.5) 0 (0.0)
Cortical thickness in the AD signature, mm 2.85 [2.79–2.91] 2.86 [2.80–2.92] 2.85 [2.76–2.93]
1Values are n (%) or mean (95% CI), except for WMH burden and cortical thickness in the AD signature, which are
median [IQR]. AD, Alzheimer disease; ALA, α-linolenic acid; WMH, white matter hyperintensity.
2Includes ε2/ε4 (n = 29) and ε3/ε4 (n = 128) genotypes.
Discussion
In this cross-sectional study conducted in middle-aged cogni-
tively unimpaired individuals from a cohort enriched by APOE-
ε4 carriership, we observed that in APOE-ε4 homozygotes
higher self-reported dietary DHA intake was related to a lower
prevalence of CBMs in lobar regions of the brain (i.e., not in the
basal ganglia) and to a greater cortical thickness in the so-called
AD signature, which includes regions known to undergo atrophy
in AD.
TABLE 2 Associations between dietary DHA and episodic memory composite scores in the studied population1
Variable Model APOE-ε4 in the model Estimate (95% CI) P R2
DHA Unadjusted — 0.039 (−0.184, 0.261) 0.733 <0.001
Adjusted2 Carrier/noncarrier3 0.006 (−0.227, 0.239) 0.957 0.021
Number of alleles4 0.005 (−0.228, 0.238) 0.964 0.021
Homozygote/nonhomozygote5 − 0.001 (−0.234, 0.233) 0.997 0.017
DHA × APOE-ε4 Unadjusted Carrier/noncarrier3 − 0.330 (−0.782, 0.123) 0.153 0.002
Adjusted6 − 0.381 (−0.836, 0.074) 0.101 0.011
Unadjusted Number of alleles4 − 0.156 (−0.454, 0.142) 0.304 0.010
Adjusted6 − 0.171 (−0.470, 0.127) 0.260 0.025
Unadjusted Homozygote/nonhomozygote5 − 0.035 (−0.599, 0.530) 0.904 0.004
Adjusted6 − 0.024 (−0.588, 0.540) 0.933 0.017
1n = 340. Data are presented for 1 g/d of DHA, obtained by multiple linear regression analyses. Episodic memory composite scores were calculated by
averaging normalized age- and education-regressed scores of all subtests in the domain. ALA, α-linolenic acid.
2Including APOE-ε4, gender, self-reported energy intake, and ALA intake as covariates.
3Distributed into n = 218 carriers and n = 122 noncarriers.
4Distributed into n = 122 with 0 alleles, n = 157 with 1 allele, and n = 61 with 2 alleles.
5Distributed into n = 61 homozygotes and n = 279 nonhomozygotes.
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TABLE 3 Associations between dietary DHA and executive function composite scores in the studied population1
Variable Model APOE-ε4 in the model Estimate (95% CI) P R2
DHA Unadjusted — − 0.038 (−0.189, 0.112) 0.617 0.001
Adjusted2 Carrier/noncarrier3 − 0.005 (−0.160, 0.151) 0.953 0.051
Number of alleles4 − 0.004 (−0.159, 0.151) 0.959 0.051
Homozygote/nonhomozygote5 − 0.005 (−0.160, 0.150) 0.951 0.051
DHA × APOE-ε4 Unadjusted Carrier/noncarrier3 − 0.121 (−0.429, 0.186) 0.438 0.004
Adjusted6 − 0.061 (−0.366, 0.243) 0.692 0.051
Unadjusted Number of alleles4 − 0.019 (−0.222, 0.184) 0.856 0.002
Adjusted6 − 0.003 (−0.203, 0.196) 0.975 0.051
Unadjusted Homozygote/nonhomozygote5 0.123 (−0.260, 0.505) 0.528 0.002
Adjusted6 0.086 (−0.289, 0.462) 0.651 0.052
1n = 340. Data are presented for 1 g/d of DHA, obtained by multiple linear regression analyses. Executive function composite scores were calculated by
averaging normalized age- and education-regressed scores of all subtests in the domain. ALA, α-linolenic acid.
2Including APOE-ε4, gender, self-reported energy intake, and ALA intake as covariates.
3Distributed into n = 218 carriers and n = 122 noncarriers.
4Distributed into n = 122 with 0 alleles, n = 157 with 1 allele, and n = 61 with 2 alleles.
5Distributed into n = 61 homozygotes and n = 279 nonhomozygotes.
6Including gender, self-reported energy intake, and ALA intake as covariates.
Three aspects of our results merit highlighting. First, despite
the increasing amount of research on diet (including nutrients,
foods, and dietary patterns) and MRI-assessed markers of AD,
this is the first study that we know of to examine how APOE-ε4
modulates the association between dietary DHA and structural
AD features in the preclinical stage. Second, we described a
beneficial association for DHA only in APOE-ε4 homozygotes.
The high prevalence of APOE-ε4 homozygotes in our sample
provided us with unprecedented statistical power to test separate
models of genetic penetrance, which may capture distinct
levels of vulnerability to risk alleles conferring a predisposition
to AD. Third, our results reinforce the hypothesis that this
genetically disadvantaged population might benefit the most from
an intervention related to dietary DHA.
We did not find any significant association between self-
reported dietary DHA intake and cognitive performance. In
addition to the limited sample size (which might complicate the
detection of weak associations), a plausible reason to explain
in part such a finding could be the fact that our participants
are highly educated and had high-range scores in most tests,
even though we used challenging cognitive tasks to avoid the
ceiling effects observed in such a population in regular tests
used at memory clinics. Similarly, we did not find any relevant
association between DHA and WMH burden, a marker of
cerebral small vessel disease which has been found to have an
impact on memory and executive functions in the same study
population (31). Despite the long-known vascular protection
ascribed to dietary intake of omega (ω)-3 fatty acids of marine
origin (32), the issue of whether intake of DHA (or consumption
of its parent foods) relates to WMH remains controversial.
Most studies on the topic to date have been conducted in US
populations. Whereas increasing blood concentrations of marine-
derived ω-3 fatty acids were found to be associated with a lesser
WMH burden in 2 cross-sectional studies (33, 34), self-reported
TABLE 4 Associations between dietary DHA and WMH burden in the studied population1
Variable Model APOE-ε4 in the model Estimate (95% CI) P R2
DHA Unadjusted — − 375 (−1232, 483) 0.391 0.002
Adjusted2 Carrier/noncarrier3 − 250 (−1119, 618) 0.571 0.112
Number of alleles4 − 234 (−1102, 633) 0.596 0.113
Homozygote/nonhomozygote5 − 244 (−1107, 618) 0.578 0.123
DHA × APOE-ε4 Unadjusted Carrier/noncarrier3 − 1488 (−3235, 259) 0.095 0.012
Adjusted6 − 918 (−2624, 788) 0.291 0.115
Unadjusted Number of alleles4 − 1089 (−2239, 62) 0.064 0.013
Adjusted6 − 661 (−1781, 459) 0.247 0.117
Unadjusted Homozygote/nonhomozygote5 − 1511 (−3682, 659) 0.172 0.011
Adjusted6 − 845 (−2944, 1253) 0.429 0.124
1n = 340. Data are presented for 1 g/d of DHA, obtained by multiple linear regression analyses. WMH burden was rank-transformed. ALA, α-linolenic
acid; WMH, white matter hyperintensity.
2Including APOE-ε4, total intracranial volume, gender, age, BMI, hypercholesterolemia, hypertension, self-reported energy intake, and ALA intake as
covariates.
3Distributed into n = 218 carriers and n = 122 noncarriers.
4Distributed into n = 122 with 0 alleles, n = 157 with 1 allele, and n = 61 with 2 alleles.
5Distributed into n = 61 homozygotes and n = 279 nonhomozygotes.
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TABLE 5 Associations between dietary DHA and prevalence of CMBs in the studied population1
Presence of CMBs, any brain area
(n = 62 cases)
Presence of CMBs, lobar brain
(n = 50 cases)
Variable Model APOE-ε4 in the model OR (95% CI) P OR (95% CI) P
DHA Unadjusted — 0.702 (0.357, 1.379) 0.304 0.469 (0.197, 1.113) 0.064
Adjusted2 Carrier/noncarrier3 0.585 (0.279, 1.228) 0.156 0.446 (0.195, 1.018) 0.055
Number of alleles4 0.578 (0.276, 1.211) 0.146 0.441 (0.193, 1.004) 0.051
Homozygote/nonhomozygote5 0.575 (0.275, 1.204) 0.142 0.445 (0.195, 1.014) 0.054
DHA × APOE-ε4 Unadjusted Carrier/noncarrier3 1.056 (0.264, 4.228) 0.939 0.566 (0.123, 2.610) 0.466
Adjusted6 1.347 (0.308, 5.894) 0.693 0.682 (0.134, 3.461) 0.644
Unadjusted Number of alleles4 1.109 (0.453, 2.717) 0.821 0.706 (0.253, 1.972) 0.506
Adjusted6 1.194 (0.462, 3.090) 0.714 0.750 (0.252, 2.230) 0.605
Unadjusted Homozygote/nonhomozygote5 1.324 (0.255, 6.873) 0.739 0.719 (0.102, 5.089) 0.741
Adjusted6 1.226 (0.224, 6.711) 0.814 0.702 (0.096, 5.151) 0.728
1n = 338. Values are ORs and 95% CIs for 1 g/d of DHA, obtained by logistic regression models, unless otherwise indicated. ALA, α-linolenic acid;
CMB, cerebral microbleed.
2Including APOE-ε4, gender, age, BMI, hypercholesterolemia, hypertension, self-reported energy intake, and ALA intake as covariates.
3Distributed into n = 216 carriers and n = 122 noncarriers.
4Distributed into n = 122 with 0 alleles, n = 155 with 1 allele, and n = 61 with 2 alleles.
5Distributed into n = 61 homozygotes and n = 277 nonhomozygotes.
6Including gender, age, BMI, hypercholesterolemia, hypertension, self-reported energy intake, and ALA intake as covariates.
fish consumption was not a significant independent predictor of
WMH burden in the Northern Manhattan Study (35). A plausible
explanation for our neutral findings on DHA and WMH other
than the limited sample size might be the existence of a threshold
of protection, largely exceeded by our population (mean DHA
intake > 0.7 g/d), above which further benefits would not be
observed. This would be similar to the prevention of ischemic
heart disease, for which few benefits are observed beyond DHA
intake of 0.5 mg/d (36). Further research is needed to elucidate
whether cerebrovascular benefits of dietary DHA would be
mainly observed in populations from countries in which fish
consumption is customarily low, e.g., the United States (37). In
contrast, we observed an inverse association between DHA intake
and the presence in lobar regions of CMBs, which have been
associated with accumulation of amyloid proteins in the walls
of blood vessels (38). Unfortunately, the absence of biomarkers
of amyloid-β deposition (determination in cerebrospinal fluid or
by amyloid-β positron emission tomography) in our population
precluded us confirming whether the inverse association between
DHA and presence of lobar CMBs is mediated by the pathway
relating DHA and amyloid-β, as has been suggested in 2 previous
observational studies (39, 40).
Of note, we also uncovered a relevant finding for dietary DHA
concerning a specific pattern of cortical areas (entorhinal, inferior
temporal, middle temporal, and fusiform regions) whose thinning
has been found to be associated with AD risk and progression
[the “AD signature” established by Jack et al. (23)]. Interestingly,
statistical significance was restricted to individuals carrying
2 copies of the APOE-ε4 allele, which are the strongest genetic
risk factor for sporadic AD, and are suggested to have higher
TABLE 6 Associations between dietary DHA and cortical thickness in the AD signature in the studied population1
Variable Model APOE-ε4 in the model Estimate (95% CI) P R2
DHA Unadjusted — 0.003 (−0.026, 0.031) 0.858 <0.001
Adjusted2 Carrier/noncarrier3 − 0.003 (−0.032, 0.026) 0.859 0.096
Number of alleles4 − 0.003 (−0.032, 0.026) 0.842 0.096
Homozygote/nonhomozygote5 − 0.003 (−0.032, 0.026) 0.848 0.099
DHA × APOE-ε4 Unadjusted Carrier/noncarrier3 0.055 (−0.002, 0.113) 0.060 0.013
Adjusted6 0.033 (−0.024, 0.089) 0.257 0.100
Unadjusted Number of alleles4 0.048 (0.010, 0.086) 0.014 0.019
Adjusted6 0.035 (−0.002, 0.072) 0.067 0.105
Unadjusted Homozygote/nonhomozygote5 0.084 (0.012, 0.155) 0.022 0.016
Adjusted6 0.071 (0.002, 0.141) 0.045 0.110
1n = 339. Data are presented for 1 g/d of DHA, obtained by multiple linear regression analyses. Cortical thickness in the AD signature was
rank-transformed. ALA, α-linolenic acid.
2Including APOE-ε4, gender, age, BMI, hypercholesterolemia, hypertension, self-reported energy intake, and ALA intake as covariates.
3Distributed into n = 217 carriers and n = 122 noncarriers.
4Distributed into n = 122 with 0 alleles, n = 156 with 1 allele, and n = 61 with 2 alleles.
5Distributed into n = 61 homozygotes and n = 278 nonhomozygotes.
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FIGURE 1 Scatterplot of the association between self-reported dietary
intake of DHA and standardized residuals of cortical thickness in the AD
signature by Jack et al. (23), outputted from a general linear model including
gender, age, BMI, hypercholesterolemia, hypertension, energy intake, and
α-linolenic acid intake, in APOE-ε4 homozygotes (n = 59, in red) and
nonhomozygotes matched for selected adjusting covariates (n = 59, in blue).
P value for the DHA × APOE-ε4 interaction = 0.025. Pearson correlation
coefficient = −0.151 (P = 0.253) for APOE-ε4 homozygotes; Pearson
correlation coefficient = 0.267 (P = 0.041) for matched nonhomozygotes.
AD, Alzheimer disease.
DHA requirements (5, 6) due to apoE-ε4-related disturbed lipid
metabolism (5). Although causality cannot be inferred in our
study given its cross-sectional nature, these 2 findings support the
potential benefits of dietary DHA in managing APOE-ε4-related
risk before symptomatology appears, as has been hypothesized
(5). This notion is in alignment with the current point of view
that lifestyle-related interventions would yield more benefits in
subpopulations at increased risk (1), which further reinforces the
need for identification of at-risk individuals.
Our study is not free of limitations. First, its cross-sectional
nature precluded us from exploring whether self-reported intake
of DHA related to longitudinal changes in MRI-assessed struc-
tural AD features. Second, we do not have data concerning core
AD biomarkers. Third, the use of objective biomarkers of DHA
intake (DHA determination in adipose tissue or RBCs) reflects
long-term exposure more accurately than DHA estimation from
self-reported food consumption. Finally, our cohort is enriched by
family history of sporadic AD and APOE-ε4 carriership, which
may limit the generalizability of the findings to other age groups
or populations. In contrast, the strengths of the present study
include the precise clinical characterization of the participants,
the large number of APOE-ε4 homozygotes, the use of a validated
FFQ, and adjustment for a wide array of potential confounders in
multivariable analyses.
In conclusion, self-reported dietary DHA was found to be
associated with several beneficial brain neuroimaging phenotypes
related to cerebrovascular pathology or AD-related neurodegen-
eration in middle-aged cognitively unimpaired individuals at
increased genetic risk of sporadic AD. Further research is needed
to explore the effectiveness of interventions involving dietary
supplementation with this fatty acid at the preclinical stage of
AD, particularly in subjects at high risk of the disease.
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